NCT00185588View on ClinicalTrials.gov

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

January 31, 2009

Study Completion Date

December 31, 2009

Conditions
Pancreatic Cancer
Interventions
DRUG

Vatalanib

Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours

DRUG

Gemcitabine

850 mg/m2

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

George Albert Fisher

OTHER